Abstract
Topiramate is approved for the preventive treatment of migraine in several countries based on the results of three large randomised, double-blind studies that showed that this compound was significantly more effective than placebo in migraine prophylaxis. We review the results of two studies: one which pooled data from the three controlled double-blind trials using 100 mg/day of topiramate, and an open-label extension of two of these trials in which patients received different topiramate doses for an eight-month maintenance period. The overall results confirm that topiramate is effective in reducing migraine frequency, and has a satisfactory tolerability profile.
Similar content being viewed by others
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bussone, G., Usai, S. & D’Amico, D. Topiramate in migraine prophylaxis: data from a pooled analysis and open-label extension study. Neurol Sci 27 (Suppl 2), s159–s163 (2006). https://doi.org/10.1007/s10072-006-0593-z
Issue Date:
DOI: https://doi.org/10.1007/s10072-006-0593-z